Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Lowered by Wall Street Zen

Tarsus Pharmaceuticals (NASDAQ:TARS) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts have also recently issued reports on the company. Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Guggenheim upped their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. HC Wainwright reaffirmed a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Finally, Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.67.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $63.16 on Friday. The company has a market cap of $2.72 billion, a PE ratio of -55.40 and a beta of 0.49. The firm’s 50 day moving average price is $63.18 and its 200-day moving average price is $69.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. Tarsus Pharmaceuticals has a 52-week low of $38.51 and a 52-week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The company had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. Sell-side analysts forecast that Tarsus Pharmaceuticals will post -0.59 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director William J. Phd Link sold 12,500 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the sale, the director owned 106,786 shares in the company, valued at approximately $6,633,546.32. This represents a 10.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Goodrich sold 2,954 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.08, for a total value of $183,384.32. Following the completion of the sale, the director directly owned 2,233 shares of the company’s stock, valued at $138,624.64. The trade was a 56.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 29,850 shares of company stock valued at $1,837,321. 9.64% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Parallel Advisors LLC boosted its holdings in Tarsus Pharmaceuticals by 139.2% in the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after acquiring an additional 291 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 367.1% during the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock valued at $50,000 after acquiring an additional 558 shares in the last quarter. Comerica Bank increased its holdings in shares of Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after acquiring an additional 705 shares in the last quarter. Truvestments Capital LLC raised its position in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares during the last quarter. Finally, Rockefeller Capital Management L.P. raised its position in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.